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Abstract: Among diabetes patients, ophthalmological complications are very frequent. High blood
glucose and (consequential) ischemia-reperfusion (I/R) injury contribute significantly to the severity of
retinopathies. Diabetic retinopathy is among the leading causes of blindness. Our study demonstrates
the effect of sour cherry seed extract (SCSE) on blood glucose and function of the retina with
electroretinography (ERG) in a diabetic setting with or without ischemia-reperfusion (I/R) injury
in Zucker Diabetic Fatty (ZDF) rats. Our results prove that the SCSE has a retinoprotective effect in
diabetic rats: according to ERG measurements, SCSE treatment mitigated the retinal function-damaging
effect of diabetes, and proved to be protective in the diabetic eye against ischemia-reperfusion injuries
of the retina. Outcomes suggest that the protective effects of SCSE may occur through several pathways,
including HO-1 dependent mechanisms. The observation that SCSE treatment decreases blood glucose
is also novel. These findings offer the possibility for development of novel therapeutic strategies
utilizing this emerging functional food, in particular in the prevention of conditions resulting from high
blood glucose or I/R injury, such as deterioration of retinal microcirculation.
Keywords: Prunus cerasus; sour cherry; ischemia-reperfusion; retina; electroretinography; ZDF rat
1. Introduction
Diabetic retinopathy [1], retinal vascular occlusion [2], and glaucoma [3] are some of the many
diseases in which ischemia-reperfusion (I/R) injury or high blood glucose levels and the resulting
deterioration of tissue microcirculatory capacity are major contributing factors. Dietary intake of
phytonutrients—health-enhancing compounds found in plants—substantially reduces the risk of
serious diseases and improves the effectiveness of therapy and outcome [4–7], even in the case of ocular
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disorders [8]. Previously, the authors of this report carried out experiments with the flavonoid-rich
extract of Prunus cerasus (sour cherry) seed (SCSE), an emerging functional food [9].
According to the results of a wide spectrum of measurements including GC-MS and HPLC,
constituents of SCSE include bio-active compounds such as dihydro-p-coumaric acid, ferrulic acid,
caffeic acid, cyanidin, peonidin, squalene, β-tocopherol, γ-sitosterol, and vitamin E, to many of which
the sour cherry extract owes its protective, antioxidant capacity [10].
Heme oxygenase 1 (HO-1), also referred to as heat shock protein (HSP) 32, has a key role in
the amelioration of oxidative stress-related pathologies, including cardiovascular, lung, neurological,
and kidney disorders [11–14]. Mahmoud et al. [15,16] established a link between SCSE and HO-1: they
demonstrated that the extract increases the expression of heme oxygenase 1 besides its antioxidant capacity.
The results of previous work by the authors of this report suggest that sour cherry seed
extract may have potential for the prevention and treatment of I/R-associated pathologies, including
diabetes-related ocular disease: previously Bak et al. [17], and later Czompa et al. [18], demonstrated
the protective effect of SCSE on ischemic-reperfused rat myocardium; Juhasz et al. [4] confirmed
a cardioprotective effect in hypercholesterolemic rabbits; and Szabo et al. [19] proved protection in
ischemic-reperfused retina. The extract was further studied toxicologically [20], which enabled the use
of SCSE even in human studies [21,22]. These results are very promising and make SCSE a potential
candidate for future drug development and further studies, such as the present one, to analyze the wide
spectrum of effects the extract may exert.
Deterioration of tissue microcirculatory capacity due to ischemia-reperfusion injury or high blood
glucose levels causes significantly adverse effects on retinal tissue, however, at the time of this writing,
the ability of SCSE to protect the functioning of the retina against ischemia-reperfusion injury in a high
blood glucose setting has not been comprehensively investigated.
The present study was conducted to evaluate the effects of sour cherry seed extract (SCSE) on
blood sugar levels in Zucker Diabetic Fatty (ZDF) rats. We also wanted to assess the function of
the retina in this insulin-intolerant animal model with the help of electroretinography (ERG). A major
goal of the experiments was to measure the effect of SCSE treatment on the alteration of retinal
function following ischemia-reperfusion injury in such a diabetic setting. We also tried to explore
an action–mechanism pathway of the retinoprotective effect of SCSE.
2. Results
2.1. Fasting Blood Sugar Analysis and Oral Glucose Tolerance Test (OGTT) Results
Figure 1 shows the blood sugar levels of the three animal groups in the fasting state as well as
after oral glucose tolerance testing (OGTT).
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Figure 1. Blood sugar levels of animals before (fasting) and after oral glucose tolerance test (OGTT). 
Values are mean ± SEM in mmol/L. ns = no significant difference; * p < 0.05; *** p < 0.001. 
2.2. Electroretinography 
The outcome of ERG measurements is shown in Figure 2, which demonstrates mean amplitudes 
of a- and b-waves (Figure 2A,B, respectively) of electroretinograms in the three animal groups. 
 
Figure 2. Electroretinographical results. (A) Mean a-wave amplitudes; (B) Mean b-wave amplitudes; 
Mean retinal a- and b-wave amplitudes elicited by light flashes were measured both in non-
ischemic/reperfused (non-I/R) and in ischemic-reperfused eyes (I/R) of the different groups. Values 
are mean ± SEM in micro-Volts (µV). ns = no significant difference; *** p < 0.001. 
Figure 1. Blood sugar levels of animals before (fasting) and after oral glucose tolerance test (OGTT).
Values are mean ± SEM in mmol/L. ns = no significant difference; * p < 0.05; *** p < 0.001.
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The fasting and OGTT blood glucose levels of the healthy animal group (5.137 mmol/L and
7.571 mmol/L, respectively) did not differ significantly from each other, as occurred in the other
two diabetic animal groups. The fasting blood glucose level of the control group (9.626 mmol/L)
was significantly different from the appropriate value of the healthy group, and apparently differed
also from the fasting value of the treated group, however this latter difference was statistically not
significant. At the same time, the fasting blood glucose level of the treated group (7.510 mmol/L) was
statistically not different from the fasting results of the healthy animals either. In the case of OGTT
blood sugar values, both diabetic groups differed significantly from healthy group values: the mean
value of the control group was 17.41 mmol/L, while that of the treated group was 14.330 mmol/L.
The difference between the control and treated groups was also significant (p < 0.05).
2.2. Electroretinography
The outcome of ERG measurements is shown in Figure 2, which demonstrates mean amplitudes
of a- and b-waves (Figure 2A,B, respectively) of electroretinograms in the three animal groups.
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(non-I/R) and in ischemic-reperfused eyes (I/R) of the different groups. Values are mean ± SEM in
micro-Volts (µV). ns = no significant difference; *** p < 0.001.
By comparing the non-IR data, it can be seen that the SCSE treatment significantly increased
the mean amplitudes of a- and b-waves relative to the control group (88.11 µV vs. 68.61 µV for
the a-waves and 233.9 µV vs. 178.7 µV for the b-waves; p < 0.001 for both comparisons); furthermore,
the mean amplitude of b-waves of the treated group did not differ significantly from the same values
of the healthy group (233.9 µV vs. 236.2 µV). In the case of a-waves, the former mentioned comparison
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results in a significant difference between treated and healthy non-I/R groups, with the treated group
being higher (88.11 µV vs. 69.85 µV).
Regarding the IR values, it can be concluded that a significant difference can be seen between
the b-wave mean amplitudes of the control group and that of the healthy animals (96.83 µV vs.
149.9 µV; control vs. healthy; p < 0.001), while the treatment increased these values significantly
(176.2 µV; p < 0.001 vs. control). It should be highlighted that the IR b-wave results of the treated
group also proved to be significantly better than the IR b-wave values of the healthy group (treated
vs. healthy; p < 0.001). Similarly, sour cherry seed extract provided better a-wave amplitudes after
ischemia-reperfusion as compared either with healthy or control groups (76.28 µV vs. 47.15 µV or
45.98 µV; treated vs. healthy or control; p < 0.001 in both comparisons).
Representative electroretinograms of each experimental group are shown in Supplementary
Materials Figure S1.
2.3. Measurement of Heme Oxygenase Concentration
The outcome of heme oxygenase concentration measurement of ocular tissue from rats of
the different groups is provided in Figure 3.
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As shown in this figure, tissue concentration of the enzyme was statistically the same in the healthy
and control groups, both pre-ischemically and after ischemia (1.170 vs. 1.115 for non-I/R and 1.717
vs. 1.469 for I/R, respectively). In the case of non-I/R eyes, a significant boost in expression is seen
in the SCSE-treated group compared to both the healthy and the control groups (2.963; p < 0.05 vs.
control and p < 0.001 vs. healthy). The elevation in ischemia protein expression in the healthy group is
the reason why the healthy vs. treated comparison lost its former strength, nevertheless, the mean
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concentration value of the treated group was still significantly higher compared with the healthy group
(2.934; p < 0.05 vs. healthy/control).
2.4. Histology Results
Quantitative histology results of ocular tissue from rats of the different groups are provided in
Figure 4.
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examined. With the help of electroretinography, the change in retinal function related to diabetes,
IR injury, and their combination, with or without SCSE administration, was investigated. Furthermore,
the change of HO-concentration in the retinal tissues of the different groups was quantified as well.
In addition, we carried out quantitative analyses on histological sections, namely measuring retinal
thickness and counting of cells in the ganglion cell layer (GCL) per unit distance in the formerly
mentioned settings.
According to our OGTT measurements, sour cherry seed extract showed a modest, but significant
blood sugar lowering effect: blood glucose levels of the diabetic animal groups were higher than
the values of the healthy animals, however, values of the treated group after oral glucose load were
improved compared with control (Figure 1). The above-mentioned findings may be explained by
the fact that long before the actual (fasting) blood glucose elevation and the appearance of clinical
diabetes, glucose intolerance develops on the basis of insulin resistance, a condition which has been
recognized as the most significant predictor of further development of type 2 diabetes mellitus [24].
Several studies have shown that phytocompounds found in fruits and vegetables have beneficial
health effects like prevention of cancer, cardiovascular diseases, and obesity [25]. Most recently,
Lachin et al. [26] published a paper on the effect of different cherries on diabetes with many promising
results: e.g., yellow cherry, sweet cherry, or tart/sour cherry fruit showed significant blood sugar
lowering effects. The data of our experiments contribute to this finding with a novel result, that
an extract made of sour cherry seed may also be modestly antidiabetic.
Data from the electroretinographical measurements provide insight into the damaging effects of
diabetes mellitus on retinal function (when comparing the non-IR results of healthy and control animals),
and allow easy comparison of functioning of IR-injured and non-IR retina in the animal groups (Figure 2).
A major finding of this current report is the significant improvement in the electrophysiological
functions of photoreceptors and retinal cells post-synaptic to photoreceptors (i.e., cells of the inner
nuclear layer (INL)) as seen on non-IR electroretinograms of the SCSE-administered group compared
with control. Despite the high blood glucose levels, retinal function of non-IR eyes of animals in
the treated group was at least similar to that of the healthy group, which is also a major finding.
This means that SCSE treatment was able to prevent the retina-damaging effect of diabetes mellitus on
the functional level: both photoreceptors and post-receptoral on pathway cells, including rod bipolar
cells, remain highly active despite the deteriorative effect of hyperglycaemia. Such retinoprotective
effects were demonstrated by other authors using treatment with resveratrol, an active agent also of
herbal origin [27], or with peptides such as GLP-1 analogue exenatide or liraglutide [28,29].
A number of ocular diseases have been associated with retinal ischemia-reperfusion injury
including diabetic retinopathy [30]. A simple method of provoking IR injury used in the present study
offered insight to the retina-damaging consequences of diabetes. Upon investigating the IR values on
our electroretinograms, it can be concluded that, while a significant deterioration in retinal function can
be seen in the control group compared with healthy animals, significant functional improvement was
demonstrated in the treated group. Furthermore, the SCSE-treated group showed significantly better
retinal function compared with the healthy animal group. This novel result supports the hypothesis
that SCSE may have capacity in preventing IR-induced retinal damage at the functional level even
in a diabetic setting. In non-diabetic rat models, our workgroup already published intriguing results
on the effect of SCSE against IR-injury [19] and also with other treatments including alpha-MSH or
PACAP [14,31]. Similarly, further potential possibilities can be found in the scientific literature for
treatment or prevention of IR-injured retina in diabetic retinopathy, such as with the GLP-1 peptide
analogue, exeantide [32].
The HO-1 enzyme may play an important role in the retinoprotective effect of sour cherry
seed extract in a diabetic setting, as could be concluded from heme oxygenase 1 (HO-1) concentration
measurements presented here (Figure 3A). Elevated blood sugar levels may imply a stress for the retinal
tissue, as the level of this well-known stress protein—although not significantly, but still—increases in
the control group as compared with healthy, low blood glucose animals. The sour cherry seed extract
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further elevated the level of this protective enzyme, which may contribute to the hypoglycemic activity
of the extract. Similar elevated heme oxygenase enzyme concentration after sour cherry seed extract
treatment was seen formerly in conventional, i.e., non-diabetic animal models in other tissues [4,16]
and even in retina as well [19]. A novel finding of this current report is that the capacity of SCSE in
elevating HO-1 levels was confirmed in a diabetic setting.
Ischemia-reperfusion damages the retina [14] as well as other tissues [12]. Based on our present
investigation the level of heme oxygenase may increase upon such injury (Figure 3B: healthy I/R group).
In the diabetic animals (control I/R group), however, the harmful effect of diabetes and ischemia-
reperfusion were added together, which may be associated with the decrease of heme oxygenase
concentration. Despite the deteriorating effects of a high-glucose setting, sour cherry seed treatment
generated a higher HO-1 concentration as compared with the healthy group, which is a novel result,
and which may be the reason behind the protective effect of the extract against ischemia-reperfusion
injury. According to our knowledge, this report is the first to suggest a retinoprotective effect of SCSE
on diabetic animals, which was connected to heme oxygenase overexpression. Similar mechanisms of
effect are not unheard of among herbal medicines: retinoprotective effects of blueberry anthocyanins
are also mediated through the Nrf2/heme oxygenase signaling pathway [8]. Based on our former
results, and those of other authors, heme oxygenase 1 is a highly potent protective agent against
ischemia-reperfusion injury [13,19,33], which was also confirmed and corroborated in our present
study. Nonetheless, it is necessary to investigate other possible mechanisms to facilitate deeper
understanding of the exact effects of SCSE. Further avenues of future experiments may include
exploring possible involvement of hypoxia-induced factor 1 alpha (HIF1-α), HIF2-α, or different heat
shock proteins such as hsp60 or 90.
Sour cherry seed extract was able to counteract the edema-inducing effect of diabetes as seen
from the comparison of treated non-I/R and control non-I/R retinal thickness values (Figure 4A).
Ischemia-reperfusion injury may also cause retinal edema [34], an effect compensated by SCSE
treatment based on retinal thickness values of ischemic-reperfused retina tissue samples (Figure 4B).
These novel results are not individual among herbal agents: such a protective effect was demonstrated
with other herbal treatments, such as Lycium barbarum [35,36], ginsenosides [37] or Flos puerariae [38].
Ganglion cell numbers did not change significantly according to our results (Figure 4C,D).
The reason behind this may be the relatively short time interval between the ischemia and tissue
sampling: the time course of ischemia-reperfusion injury starts with initial retinal edema, followed
by structural degenerative changes which need more time to develop, i.e., a consequential cell death,
e.g., a decrease in number of ganglion cells [34].
All things considered, according to our data presented here, SCSE may have the capacity to
alleviate the damaging effect of high blood glucose and protect the retina from I/R injuries in
diabetic conditions. Although this extract will not be the first choice for lowering blood glucose
levels, nevertheless there are many other drugs for that purpose to choose from, and an agent can
indeed have a potent retinoprotective effect in diabetic retinopathy without being effective against
hyperglycaemia [29]. Formulation of new drugs from such synergistic agents—be it of herbal origin or
not—can result in the successful treatment of an unmanageable disease such as diabetic retinopathy.
For this reason, our observations also bear a high potential from a clinical point of view. Development
of a future therapy based on SCSE may possess pharmaceutical significance as well.
4. Materials and Methods
4.1. Animals and Groups
At the start of the present study, 6-week-old male Zucker Diabetic Fatty (ZDF-Leprfa/Crl) rats
and their control (lean phenotype) were purchased from Charles River Laboratories International, Inc.
(Wilmington, MA, USA). All animals received humane care in compliance with the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research and the NIH guidelines. All of the protocols
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used in the present study were approved by the Institutional Animal Care Committee of University
of Debrecen in Debrecen, Hungary (18/2013/DE MÁB). The animals were fed a Purina 5008 diet ad
libitum for 50 days, and had free access to water.
Rats were separated into three groups (n = 6 in each group): a control diabetic group, a treated
diabetic group, and a healthy group. The treated group was gavaged with 30 mg/kg SCSE daily, while
the control group was gavaged with the vehicle only (methyl-cellulose mucilage) according to former
protocol [17].
4.2. Ocular Ischemia and Reperfusion (I/R)
At the end of the 50-day period, rats were anaesthetized with an intramuscular ketamin/xylazine
(50/5 mg/kg) injection. The eyes of the animals were locally anaesthetized with 0.4% oxybuprocain
eyedrops as well (Humacain, Teva, Debrecen, Hungary). Subsequently, the retinal artery of the left eye
of each animal was surgically occluded to cut off the blood supply using a protocol previously applied
by the authors [14,34]. A silk suture thread guided through a polyethylene cannula was placed loosely
behind the eyeball around the optic nerve, central retinal artery, ciliary arteries, and the retrobulbar
connective tissue. By pulling the suture and pressing the tube against the surface of the optic nerve
this traction-type occluder induced retinal artery blockage, which could be maintained for the required
length of time (1 h). Ischemia was verified macroscopically with a 120-D lens. During ischemia the eye
of the rats was covered with sterile gauze. To prevent the drying out of the cornea, carbomer-based
eye gel was also used (Vidisic, Bausch&Lomb, Berlin, Germany). Reperfusion of the retinal tissue was
accomplished by post-ischemic release of the occluder, allowing resumption of blood flow through
the retinal artery.
4.3. Electroretinography (ERG)
After 24 h of reperfusion, animals were prepared for electroretinographic measurements by
anesthesia with an intramuscular injection of 50/5 mg/kg of ketamin/xylazine. The pupils of each
animal were dilated with 0.5% cyclopentolate hydrochloride (Humapent, Teva, Debrecen, Hungary).
Five silver electrodes were used for each measurement as follows. At the corneal surfaces, retinal
signals were analyzed using two measuring electrodes (one on each eye), inserted so as to avoid scleral
damage or corneal perforation. Reference electrodes were positioned on the earlobes of each animal
(one on each earlobe), with the main ground electrode at the glabella. Effective electrical contacts and
protection of eyes from dehydration was provided by carbomer-based eye gel (Vidisic, Bausch&Lomb,
Berlin, Germany). The ERG measurements were carried out in darkness, after a dark adaptation period
(20 min) based on the guidelines of the International Society for Clinical Electrophysiology of Vision
(ISCEV) [39]. For stimulation of the retina, the eyes were illuminated with a stroboscope (20 cd/m2,
0.5 Hz) [39]. Electrical signals, i.e., retinal responses to light flashes, passed through an amplifier
and an analog–digital converter (Bridge Amp and PowerLab, ADInstruments, Sydney, Australia),
displayed on a PC monitor, recorded and analyzed using PowerLab Chart software (Version 5.2.2.,
ADInstruments, Sydney, Australia).
The outcome of the electroretinography experiments formerly conducted by the authors demonstrated
that the aforementioned experimental strategy provides reproducible, cost-effective data on retinal
function, closely correlated to the survival of the retinal cells [14,31].
4.4. Oral Glucose Tolerancy Test (OGTT)
Oral glucose tolerancy testing was carried out two times during the experiment: first, when
the animals got involved in the experiment, and second, at the end of the 50 day treatment period.
Twelve hours before the test, food was withdrawn from the animals. During the test, fasting
glucose levels were obtained first, then 1 g/mL glucose solution was prepared with water, which
then—after heating to body temperature—was gavaged into the stomach of each animal in a dose
of 3 g/kg. One hour after the glucose-load, the blood sugar levels of the animals were measured
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again. The measurement was carried out using an AccuChek Active blood sugar monitor, which was
formerly calibrated by the blood test laboratory of our clinic.
4.5. Measurement of Heme Oxygenase Concentration
After the ERG measurements, the eyeballs of the animals were removed for further
analysis. Half of the enucleated bulbi were suspended in a homogenization buffer composed of
N-2-hydroxyethylpiperazine-2-ethanesulfonic acid (HEPES) 10 mM, sucrose 32 mM, dithiotreitol
(DTT) 1 mM, ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA) 0.1 mM, soybean trypsin
inhibitor 10 µg/mL, Leupeptin 10 µg/mL, Aprotinin 2 µg/mL; pH 7.4 (Sigma-Aldrich, St. Louis, MO,
USA). The supernatant was collected by a 30 min centrifugation of the homogenate at 20,000× g at
4 ◦C. The HO-1 content was determined by enzyme-linked immunosorbent assays (ELISA) according
to the manufacturer’s directions (Sunred Biotechnology Company, Shanghai, China). Optical density
was measured at 450 nm (Benchmark Microplate reader; Bio-Rad, Hercules, CA, USA) and the values
were expressed as ng/mg protein.
4.6. Processing for Examination by Light-Microscopy
The other half of the enucleated bulbi were processed according to the following general
protocol: the vitreum of each eye was removed and the bulbs were fixed in Bouin-solution,
alcohol-dehydrated, paraffinized, and were processed into 7 µm sagittal sections, which were then
dyed with hematoxylin-eosin (HE) and examined by light microscopy.
Average retinal thickness was measured between the inner limiting membrane and the retinal
pigment epithel (ILM-RPE) and expressed in micrometers using a manual scale on each glass slide.
The number of cells in the ganglion cell layer per unit distance (100 µm) was also counted with
the help of the same manual scale on each glass slide.
For the quantitative analyses, 6 eyes per group and 6 sections per eye were analyzed.
4.7. Statistical Analysis
A one-way analysis of variance with a Tukey or Newman–Keuls post-test was used for Gaussian
data results from the D’Agostino & Pearson omnibus normality test. Data with non-parametric
distribution were analyzed using the Kruskal–Wallis test along with the Dunns post-test. Figures are
represented with standard error of the mean (SEM).
Supplementary Materials: The following are available online. Figure S1: Representative electroretinograms for
each experimental group, Figure S2: Hematoxylin-eosin-dyed representative sections of retinae from bulbi of
the different groups. (a): healthy non-I/R; (b): control non-I/R; (c): treated non-I/R; (d): healthy I/R; (e): control
I/R; (f): treated I/R.
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